
Please try another search
For the three months ended 31 March 2022, Dongwha Pharm Co Ltd revenues increased 19% to W85.29B. Net income decreased 4% to W5.24B. Revenues reflect Pharmaceuticals segment increase of 18% to W79.21B, Medical Equipment Manufacturing and Sales segment increase of 31% to W6.08B, South Korea segment increase of 17% to W79.99B, Overseas segment increase of 62% to W5.3B.
Period Ending: | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
---|---|---|---|---|
Total Revenue | 83455.52 | 87218.16 | 85294.13 | 76317.38 |
Gross Profit | 43625.24 | 46801.82 | 44662.2 | 40840.86 |
Operating Income | 7419.26 | 10093.49 | 9053.12 | 6295.19 |
Net Income | 5944.21 | 6015.97 | 5236.78 | 5710.17 |
Period Ending: | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
---|---|---|---|---|
Total Assets | 468461.63 | 463911.71 | 459969.63 | 447804.49 |
Total Liabilities | 95304.43 | 97509.79 | 113465.41 | 100869.56 |
Total Equity | 373157.2 | 366401.92 | 346504.22 | 346934.92 |
Period Ending: | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 6996.54 | 4794.22 | 16572.33 | 36031.21 |
Cash From Investing Activities | -2887.34 | -30621.43 | 3139.72 | -25413.87 |
Cash From Financing Activities | -4611.79 | -691.67 | -5309.83 | -8782.89 |
Net Change in Cash | -190.17 | -26474.6 | 14505.36 | 1883.21 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review